Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest brain disorders Stories

2014-04-11 00:21:56

LONDON, April 11, 2014 /PRNewswire/ -- - Hepatic encephalopathy (HE) is associated with a significant increase in mortality (58.1% vs. 32.4%), as well as longer hospital stays (8 days vs. 6.8 days) and more primary care visits (18.2 vs. 8.7 contacts per patient year) compared to similar liver patients without HE[i],[ii] - XIFAXAN(R) 550 (rifaximin-alpha) is a cost-effective treatment option for the...

2013-09-09 12:27:29

LONDON, September 9, 2013 /PRNewswire/ -- Norgine today announced that the Scottish Medicines Consortium (SMC) has accepted the use, within NHS Scotland, of TARGAXAN(R) 550 (rifaximin-alpha),[i] a treatment licensed for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients of 18 years of age and over.[ii] (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) This is the second acceptance for use made by a health technology...

2013-05-24 08:22:25

LONDON, May 24, 2013 /PRNewswire/ -- Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy (HE) where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition associated with liver disease. XIFAXAN 550 mg is the only treatment that has demonstrated a...

2013-04-25 19:49:37

Probiotics could emerge as a treatment plan to manage hepatic encephalopathy (HE) therapy after a new study announced at the International Liver Congress 2013 found they significantly reduced development of the notoriously difficult-to-treat disease. The study analysed the efficacy of probiotics in preventing the development of HE in 160 cirrhotic patients over a period of approximately nine months and found significant improvements in reducing patients' arterial ammonia levels after three...

2013-04-08 12:24:04

Also in This Edition: Jobs for Writers and Media Industry Blog Posts NEW YORK, April 8, 2013 /PRNewswire/ -- Below are experts from the ProfNet network that are available to discuss timely issues in your coverage area. If you are interested in interviewing any of the experts, please contact them via the contact information at the end of the listing. To receive updates by email, drop us a note at profnet@profnet.com with the industries you cover, and we'll add you to the appropriate...

2012-11-11 08:20:20

BOSTON, Nov. 11, 2012 /PRNewswire/ -- Minimal hepatic encephalopathy (MHE), which is often found in patients with cirrhosis, is difficult to diagnose. This is an important issue because MHE is associated with poor quality of life, progression to severe disease, unemployment, and traffic accidents and can be treated if it is diagnosed. A smartphone app for Stroop task, which is used to evaluate psychomotor speed and cognitive flexibility, could be used to screen for MHE....

2012-06-22 12:03:36

The same growth factor was previously shown to reverse memory decline in Alzheimer´s mice Growth factors shown to cure Alzheimer´s disease in a mouse model and administered to cancer patients as part of their treatment regimen were linked to significant improvements in the patients´ cognitive function following stem cell transplantation, a preliminary clinical study reports. The findings by researchers at the USF Health Byrd Alzheimer´s Institute and Moffitt Cancer...

2012-04-26 02:29:39

ATLANTA, April 26, 2012 /PRNewswire/ -- Elekta, a leading international technology and solutions provider for the treatment of cancer and brain disorders, is relocating its North America headquarters in 2012. Elekta's new HQ will be The Terraces in Atlanta's Central Perimeter business district. The company anticipates adding more than 100 new jobs over five years in the life sciences field, specifically in the medical device and healthcare IT sectors. "Elekta's global influence in healthcare...

2011-11-10 13:00:00

TITUSVILLE, N.J., Nov. 10, 2011 /PRNewswire/ -- Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") today announced the launch of Healthy Minds, a comprehensive initiative to accelerate progress in the fight against brain disorders that affect millions of people around the world. Healthy Minds includes a significant new commitment by Janssen Pharmaceuticals, Inc. of $3 million in direct and challenge contributions to the International Mental Health Research Organization...

2011-08-29 12:43:00

Win up to $1,000 and a Trip to New Orleans ST. PAUL, Minn., Aug. 29, 2011 /PRNewswire-USNewswire/ -- The American Academy of Neurology Foundation is calling on all neurology patients and caregivers to submit a short video to its 2012 Neuro Film Festival, telling their story about why more research is needed into finding cures for brain disorders. Winners could receive up to $1,000 and a trip to New Orleans. The deadline to enter is January 31, 2012, at http://www.NeuroFilmFestival.com....